Minimally-Invasive Mitral and Tricuspid Valve Surgery - Direct Vision for Complex Cases

Torsten Doenst (Jena)1, P. Berretta (Ancona)2, N. Bonaros (Innsbruck)3, C. Savini (Bologna)4, A. Pitsis (Thessaloniki)5, M. Wilbring (Dresden)6, M. Gerdisch (Indianapolis)7, J. Kempfert (Berlin)8, M. Rinaldi (Turin)9, T. Folliguet (Paris)10, T. Yan (Sydney)11, P. Stefano (Firenze)12, F. Van Praet (Aalst)13, L. Salvador (Vicenza)14, J. Lamelas (Miami)15, T. C. Nguyen (Houston)16, N. Hoang Dinh (Ho Chi Minh City)17, G. Färber (Jena)1, M. Di Eusanio (Ancona)2

1Friedrich-Schiller-University Jena, University Hospital Department of Cardiothoracic Surgery Jena, Deutschland; 2Polytechnic University of Marche, Lancisi Cardiovascular Center Cardiac Surgery Unit Ancona, Italien; 3Medical University of Innsbruck Department of Cardiac Surgery Innsbruck, Österreich; 4University of Bologna, Sant’Orsola Malpighi Hospital Cardiac Surgery Department Bologna, Italien; 5European Interbalkan Medical Center Cardiac Surgery Department Thessaloniki, Griechenland; 6University Heart Center Dresden Center for Minimally Invasive Cardiac Surgery Dresden, Deutschland; 7Franciscan Health Indianapolis Indianapolis, USA; 8German Heart Center Berlin Department of Cardiothoracic and Vascular Surgery Berlin, Deutschland; 9University of Turin Cardiac Surgery Unit Turin, Italien; 10Henri Mondor Hospital, University of Paris Paris, Frankreich; 11The Royal Prince Alfred Hospital Department of Cardiothoracic Surgery Sydney, Australien; 12Careggi University Hospital Cardiac Surgery Unit Firenze, Italien; 13Hartcentrum OLV Aalst Cardiac Surgery Department Aalst, Belgien; 14S. Bortolo Hospital Division of Cardiac Surgery Vicenza, Italien; 15University of Miami Division of Cardiothoracic Surgery Miami, USA; 16University of Texas Health Science Center Houston Department of Cardiothoracic and Vascular Surgery Houston, USA; 17University of Medicine and Pharmacy Ho Chi Minh City, Vietnam

 

Purpose:
Minimally-invasive access has become routine for mitral and tricuspid valve surgery. We assessed the type of valve exposure (direct vision, video-assisted, fully endoscopic or robotic) and compared pre-operative characteristics and post-operative outcomes of a large cohort of patients (international Mini-Mitral Registry) undergoing mitral and tricuspid valve interventions. 
Methods:
From 2015-2021, 7,513 consecutive patients underwent mini-MVR±TVR in 17 international Heart-Valve-Centres. Data were collected according to MVARC definitions and 6463 patients undergoing first time mitral with or without tricuspid valve surgery were analysed. Uni- and multivariable regression analyses were performed to compare the different approaches. The table shows group sizes and main outcomes.
Results:
All patients were on average 65 years (57% male) with a Median EuroSCORE II of 1.3% (IQR: 0.80-2.63). Endoscopes and specifically the robot were used in selected patients with lower risk profile compared with direct vision (direct vision pts were older, with more comorbitities). The number of robotic cases was miniscule (0.9%) and patients were lowest risk. Concomitant tricuspid repair was performed more using direct vision or video-assisted. Operative times were shortest with direct vision. Main outcomes were similar (mortality, stroke, AKI) with varying individual endpoints (Table 1). On adjusted analysis (with "video-assisted” set as the reference approach), direct vision appeared as protective against long ventilation and wound complications and as risk factor for low cardiac output and longer length of stay. Fully endoscopic approach did not significantly affect any of the outcomes. 
Conclusions:
Direct vision in minimal-access mitral plus/minus tricuspid valve surgery is the preferred choice for more complex cases, while endoscope and robot are used more selectively. Mastering both techniques may optimize patient care.

Table 1: Demographics and Outcomes
  Video assisted

(n= 2850)

N (%)
 Direct-vision

(n=1594)

n (%)

Fully endoscopic

(n=1963)

n (%) 

Robotic

(n=56)

n (%) 
P value 
Male 1619 (57.1) 918 (57.6) 1210 (61.6)39 (69.6)  0.003
Age, median (IQR) 64 (53–72) 66 (57-74) 64 (53-73) 60 (52-68) <0.001
NYHA III-IV 1227 (43.3) 689 (51.3) 875 (44.8) 12 (21.4) <0.001
MV regurgitation (moderate-severe) 2685 (94.3) 1428 (89.6) 1896 (96.6) 56 (100) <0.001
Tricuspid regurgitation (moderate-severe) 763 (27.3) 374 (23.6) 502 (25.6) 3 (5.4) <0.001
LVEF<50% 450 (16.0) 339 (22) 264 (13.5)7 (12.5) <0.001
ES II, median (IQR) 1.1 (0.7-1.9) 1.5 (0.8-2.8) 1.2 (0.8-2.2) 1.6 (1.3-2.2) <0.001
Mitral valve repair 2141 (75.1) 1209 (75.8) 1727 (88) 51 (91.1) 
Mitral valve replacement 667 (23.4) 369 (23.1) 222 (11.3) 5 (8.9) 
Concomitant Tricuspid surgery 399 (20) 342 (21.5) 259 (13.3) 2 (3.6) <0.001
CPB time (minutes), median (IQR) 130 (98-170) 120 (98.8-145.3) 145 (119-182) 129 (99-147) <0.001
X-Clamp time (minutes), median (IQR)  87 (65-113) 65 (52-84) 90 (71-113) 183 (147-211) <0.001
Technical success 2653 (96.2) 1365 (99.3) 1880 (97.6) 56 (100) <0.001
In-hospital mortality  34 (1.2) 22 (1.4) 26 (1.3) - 0.8
30-day mortality 38 (1.9) 27 (2.2) 29 (1.7) - 0.5
Stroke 40 (1.4) 16 (1) 22 (1.1) - 0.5
Intubation time (hours), median (IQR) 9.4 (6-14) 5 (3-8) 7.7 (5-13) 1 (0-6) <0.001
Low cardiac output 88 (3.2) 83 (5.6) 47 (2.4) 4 (7.4) <0.001
Acute kidney injury  147 (5.2) 89 (6.5) 109 (7.2) 3 (5.6)0.06 
Diese Seite teilen